Highlights
- Compumedics is growing high-margin SaaS subscriptions while also expanding international hospital sales of its neurodiagnostic monitoring hardware.
- Somfit is a wearable EEG product that records brain activity outside the traditional laboratory setting.
- Clinical neuro-diagnostic hardware provides the installed base on which the company's cloud-based subscription Revenue can steadily build over time.
- Cloud-based Somfit software streams give the company Recurring Revenue that complements one-off equipment sales to hospitals and clinics worldwide.
The most telling data about sleep and the brain is often recorded overnight, and Compumedics (ASX:CMP) wants that data captured with less fuss. Its Somfit wearable EEG, plus cloud software sold by subscription, sits beside a hardware Business serving hospitals around the world.
Two Revenue Engines
The company sells clinical neuro-diagnostic hardware and is building cloud-based subscription streams around Somfit. Equipment sales are lumpy, while subscriptions repeat, so growing the second can smooth the Earnings profile over time.
About the Company
Compumedics develops and supplies equipment that measures brain and sleep activity, including EEG and polysomnography systems used by hospitals and clinics. Its products serve neurologists and sleep specialists who need reliable recordings for diagnosis.
The Wearable Angle
Somfit moves part of the recording from the clinic to the patient. A wearable EEG can capture brain activity during natural sleep, which can be more representative than a short session in an unfamiliar setting.
Management's Focus
Leadership is growing high-margin SaaS subscriptions and international hospital monitoring hardware sales. Software margins can exceed hardware margins because each additional subscriber adds little extra cost.
Sector Context
Sleep disorders and neurological conditions drive steady Demand for diagnostic tools, and health systems increasingly look for ways to test patients outside costly hospital beds.
What to Watch
Subscription numbers, new hospital installations and international orders are the practical signals of progress.
Risks to Watch
Hospital budgets, regulatory clearances and competition in diagnostic devices can slow adoption. Announcements lodged on the ASX will clarify how the mix is shifting.






Please wait processing your request...